News | June 09, 2008

Ultrasound Contrast Agent Safe During Stress Echocardiogram

June 10, 2008 - The use of ultrasound contrast agents during stress echocardiograms is safe, according to results presented at the 19th Annual Scientific Sessions of the American Society of Echocardiography.

These findings are significant after the FDA mandated a black box warning on labels of contrast agents used for cardiovascular ultrasound.

The research, conducted at the Methodist DeBakey Heart and Vascular Center in Houston, TX, showed the risk of major adverse effects is no different in patients that received contrast during their stress echocardiogram than in those who did not receive contrast, according to research findings. This held true even though contrast was more often used in patients with a higher cardiac risk profile.

The study examined 3,121 consecutive patients who underwent stress echocardiograms from 2002 through 2007 at The Methodist Hospital.

Researchers evaluated demographics, contrast use, hemodynamics, ECG and wall motion changes, symptoms and arrhythmias. Contrast was administered in 1,879 of 3,121 patients (60 percent). None of the patients receiving an ultrasound contrast agent experienced sustained ventricular tachycardia, ventricular fibrillation, cardiac arrest or death.

"Contrast-enhanced stress echocardiography is a safe option to attain important diagnostic information for patients who need more testing than cardiac ultrasound alone," said Kamran Shaikh, M.D., postdoctoral echocardiography fellow at the Methodist DeBakey Heart and Vascular Center. "Our research found no link between its use and adverse events or any reason why it shouldn't be available to cardiologists whose patients would benefit from it."

For more information: www.debakeyheartcenter.com

Related Content

ITN Wins Jesse H. Neal Award for Best Technical Content
News | Radiology Business | April 24, 2019
April 24, 2019 — Imaging Technology News (ITN) was recently named the 2019 Jesse H.
Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis
One of the most controversial issues in radiology in recent years has been the use of...
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...
Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...